- Home
- IMCR vs MNKD Comparison
IMCR vs MNKD Comparison
Compare IMCR & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- MNKD
- Stock Information
- Founded
- IMCR 2008
- MNKD 1991
- Country
- IMCR United Kingdom
- MNKD United States
- Employees
- IMCR N/A
- MNKD N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- IMCR Health Care
- MNKD Health Care
- Exchange
- IMCR Nasdaq
- MNKD Nasdaq
- Market Cap
- IMCR 1.7B
- MNKD 1.7B
- IPO Year
- IMCR 2021
- MNKD 2004
- Fundamental
- Price
- IMCR $34.26
- MNKD $5.72
- Analyst Decision
- IMCR Buy
- MNKD Strong Buy
- Analyst Count
- IMCR 9
- MNKD 5
- Target Price
- IMCR $57.00
- MNKD $10.80
- AVG Volume (30 Days)
- IMCR 287.1K
- MNKD 3.8M
- Earning Date
- IMCR 11-05-2025
- MNKD 11-06-2025
- Dividend Yield
- IMCR N/A
- MNKD N/A
- EPS Growth
- IMCR N/A
- MNKD 149.32
- EPS
- IMCR N/A
- MNKD 0.11
- Revenue
- IMCR $356,145,000.00
- MNKD $301,736,000.00
- Revenue This Year
- IMCR $29.71
- MNKD $16.36
- Revenue Next Year
- IMCR $11.27
- MNKD $20.34
- P/E Ratio
- IMCR N/A
- MNKD $52.68
- Revenue Growth
- IMCR 26.78
- MNKD 21.48
- 52 Week Low
- IMCR $23.15
- MNKD $3.38
- 52 Week High
- IMCR $39.33
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- IMCR 49.34
- MNKD 63.58
- Support Level
- IMCR $33.92
- MNKD $5.33
- Resistance Level
- IMCR $37.00
- MNKD $5.90
- Average True Range (ATR)
- IMCR 1.45
- MNKD 0.21
- MACD
- IMCR -0.06
- MNKD -0.02
- Stochastic Oscillator
- IMCR 39.78
- MNKD 77.46
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.